A Study of Ustekinumab Treatment in Children With Crohn's Disease

Real-world Evidence for the Effectiveness and Safety of Ustekinumab Treatment in Children With Crohn's Disease: A Retrospective Cohort Study Using the ImproveCareNow Registry Data

The purpose of this study is to evaluate the effectiveness of ustekinumab in achieving clinical remission in pediatric participants (greater than or equal to [>=] 2 to less than [<] 18 years and weight >= 40 kilograms [kg] at baseline).

Inclusion Criteria:

• Having at least one ICN visit with documented new use of ustekinumab
• Participants with a documented Crohn's disease (CD) diagnosis at the time ustekinumab was initiated (that is, Baseline); If diagnosis at baseline is missing, then the diagnosis from previous visit within study window will be utilized
• Having at least one ICN visit prior to the ICN visit when ustekinumab is first documented
• Having received first dose of ustekinumab on or before June 22, 2019
• Having provided informed consent for use of ICN data for research purposes

Exclusion Criteria:

• Documented exposure to ustekinumab before enrollment in ICN (by chart review)